JP2023534847A5 - - Google Patents

Info

Publication number
JP2023534847A5
JP2023534847A5 JP2023504420A JP2023504420A JP2023534847A5 JP 2023534847 A5 JP2023534847 A5 JP 2023534847A5 JP 2023504420 A JP2023504420 A JP 2023504420A JP 2023504420 A JP2023504420 A JP 2023504420A JP 2023534847 A5 JP2023534847 A5 JP 2023534847A5
Authority
JP
Japan
Prior art keywords
antibody
fusion protein
cdrs
cytokine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534847A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062907 external-priority patent/WO2022019945A1/en
Publication of JP2023534847A publication Critical patent/JP2023534847A/ja
Publication of JP2023534847A5 publication Critical patent/JP2023534847A5/ja
Pending legal-status Critical Current

Links

JP2023504420A 2020-07-20 2020-12-02 Il-10を含む二重サイトカイン融合タンパク質 Pending JP2023534847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063054208P 2020-07-20 2020-07-20
US63/054,208 2020-07-20
PCT/US2020/062907 WO2022019945A1 (en) 2020-07-20 2020-12-02 Dual cytokine fusion proteins comprising il-10

Publications (2)

Publication Number Publication Date
JP2023534847A JP2023534847A (ja) 2023-08-14
JP2023534847A5 true JP2023534847A5 (cg-RX-API-DMAC7.html) 2023-12-11

Family

ID=79291996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504420A Pending JP2023534847A (ja) 2020-07-20 2020-12-02 Il-10を含む二重サイトカイン融合タンパク質

Country Status (11)

Country Link
US (19) US11292822B2 (cg-RX-API-DMAC7.html)
EP (1) EP4181957A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023534847A (cg-RX-API-DMAC7.html)
KR (1) KR20230096959A (cg-RX-API-DMAC7.html)
CN (1) CN116322785A (cg-RX-API-DMAC7.html)
AU (1) AU2020459746A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001187A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186753A1 (cg-RX-API-DMAC7.html)
IL (1) IL300062A (cg-RX-API-DMAC7.html)
MX (1) MX2023000948A (cg-RX-API-DMAC7.html)
WO (1) WO2022019945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Il13を含む融合タンパク質
CN116322785A (zh) * 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
JP2024546999A (ja) * 2021-12-16 2024-12-26 デカ バイオサイエンシーズ, インコーポレイテッド Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー
AU2023225954A1 (en) * 2022-02-22 2024-09-05 Deka Biosciences, Inc. Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins
IL328577A (en) * 2023-11-24 2026-07-01 Medpacto Inc Fusion protein that specifically binds to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfβ) and its use
CN122555725A (zh) * 2024-01-08 2026-08-11 上药生物治疗(香港)有限公司 膜表达il-10及其用途
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞,其制备方法及抗纤维化的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
WO2004021861A2 (en) * 2002-09-03 2004-03-18 Vit Lauermann Targeted release
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
EP2209805B1 (en) 2007-10-30 2017-09-06 Philogen S.p.A. An antigen associated with rheumatoid arthritis
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
JP2013534813A (ja) * 2010-05-26 2013-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗cd133抗体一本鎖可変断片、及びこれらの使用
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2872964T3 (es) 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
CN104245719B (zh) 2011-12-12 2016-09-14 宾夕法尼亚大学托管会 包含改进的il-12基因构建体的组合物和疫苗、免疫治疗剂及其使用方法
US20150038678A1 (en) 2012-02-29 2015-02-05 Ambrx, Inc. Interleukin-10 Polypeptide Conjugates and Their Uses
US9346872B2 (en) * 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
EP2903629B1 (en) * 2012-10-03 2019-07-10 Philogen S.p.A. Antibody conjugate for use in treating inflammatory bowel disease
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
JP2016519111A (ja) 2013-04-26 2016-06-30 フィロゲン エスピーエー 細胞外マトリックス成分に対する抗体にコンジュゲートしたil4
BR112016016658A2 (pt) 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and preparations for the treatment of autoimmune and inflammatory conditions
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR101811050B1 (ko) 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
WO2017091611A1 (en) 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
WO2017178562A1 (en) 2016-04-12 2017-10-19 Philogen S.P.A. Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018156791A1 (en) 2017-02-22 2018-08-30 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
WO2018213335A1 (en) * 2017-05-16 2018-11-22 Scalmibio, Inc. Activatable antibodies and methods of use thereof
WO2019201866A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
CN114072164A (zh) * 2019-03-06 2022-02-18 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
EP4087947A4 (en) * 2020-01-09 2024-05-01 Deka Biosciences, Inc. METHODS OF USING GENETIC MARKERS, SNPS AND/OR INDELS TO DETERMINE SENSITIVITY TO IL-10 TREATMENT
CN115867275A (zh) 2020-04-13 2023-03-28 大学健康网络 治疗细胞因子释放综合征的方法
CN116322785A (zh) 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
KR20240007204A (ko) 2021-05-11 2024-01-16 싱가포르 헬스 서비시즈 피티이 엘티디 키메라 항원 수용체 및 이를 포함하는 변형된 세포
KR20240156653A (ko) 2021-12-13 2024-10-30 데카 바이오사이언시즈, 인크. 다중-서브유닛 시토카인을 포함하는 이중 시토카인 융합 단백질
JP2024546999A (ja) 2021-12-16 2024-12-26 デカ バイオサイエンシーズ, インコーポレイテッド Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー
AU2023225954A1 (en) 2022-02-22 2024-09-05 Deka Biosciences, Inc. Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins

Similar Documents

Publication Publication Date Title
IL300062A (en) Dual fused cytokine proteins containing IL-10
JP2024546938A5 (cg-RX-API-DMAC7.html)
JP2022524018A5 (cg-RX-API-DMAC7.html)
Strohl et al. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells
US20210061925A1 (en) Trispecific and/or trivalent binding proteins
Dimitrov et al. Therapeutic antibodies: current state and future trends–is a paradigm change coming soon?
Nelson Antibody fragments: hope and hype
CN105777906B (zh) 抗pd-l1全人抗体及其应用
JP2023513003A5 (cg-RX-API-DMAC7.html)
Lu et al. Technological advancements in antibody-based therapeutics for treatment of diseases
RU2451689C2 (ru) Новые антипролиферативные антитела
JP2021516975A5 (cg-RX-API-DMAC7.html)
JP2021516974A5 (cg-RX-API-DMAC7.html)
JP2021516976A5 (cg-RX-API-DMAC7.html)
Teillaud From whole monoclonal antibodies to single domain antibodies: think small
JP2021515566A5 (cg-RX-API-DMAC7.html)
IL313525A (en) Dual cytokine fusion proteins containing multisubunit cytokines
Roselli et al. CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al.
RU2007145419A (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JP2022551836A (ja) Bcmaを標的とする抗体、二重特異性抗体及びその用途
Asano et al. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody
Sadeghalvad et al. Introduction on monoclonal antibodies
JP2024546999A5 (cg-RX-API-DMAC7.html)
JP2025508882A5 (cg-RX-API-DMAC7.html)
US20220119553A1 (en) Trispecific and/or trivalent binding proteins